Non Small Cell Lung Cancer News and Research RSS Feed - Non Small Cell Lung Cancer News and Research

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Increased use of SBRT linked to improved survival outcomes of NSCLC patients

Increased use of SBRT linked to improved survival outcomes of NSCLC patients

A new analysis of records in the Veteran's Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in recent years, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Yale researchers compare efficacy of four PD-L1 assay tests

Yale researchers compare efficacy of four PD-L1 assay tests

In a recent study, a Yale Cancer Center team compared the performance of the four available PD-L1 assay tests. [More]
Study compares survival outcomes of two recommended lung cancer staging strategies

Study compares survival outcomes of two recommended lung cancer staging strategies

In a study appearing in the September 13 issue of JAMA, Jouke T. Annema, M.D., Ph.D., of the Academic Medical Center, Amsterdam, and colleagues examined five-year survival after endosonography vs mediastinoscopy for mediastinal nodal staging of lung cancer. [More]
Combinational analysis of FISH and IHC detects NSCLC patients with rare ALK fusions

Combinational analysis of FISH and IHC detects NSCLC patients with rare ALK fusions

The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment. [More]
Liquid biopsies may be effective option for detecting mutations in advanced lung cancer patients

Liquid biopsies may be effective option for detecting mutations in advanced lung cancer patients

For patients with advanced lung cancer, a non-invasive liquid biopsy may be a more effective and suitable alternative to the gold standard tissue biopsy to detect clinically relevant mutations and help guide their course of treatment, suggests a new study published this week in the journal Clinical Cancer Research from researchers at the Abramson Cancer Center at the University of Pennsylvania. [More]
Whole brain radiotherapy offers no quality-of-life benefit in lung cancer patients with brain metastases

Whole brain radiotherapy offers no quality-of-life benefit in lung cancer patients with brain metastases

People with the most common type of lung cancer whose disease has spread to the brain could be spared potentially harmful whole brain radiotherapy, according to new research published in The Lancet. [More]
HIF-2 inhibitors could be promising target to combat kidney cancer

HIF-2 inhibitors could be promising target to combat kidney cancer

A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found. [More]
Study collects data on 30-day mortality for breast, lung cancer patients after SACT to improve patient care

Study collects data on 30-day mortality for breast, lung cancer patients after SACT to improve patient care

For the first time, national data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy have been collected and analysed in order to help clinical teams review and improve patient care, and identify groups of patients who may have additional needs. [More]
Study shows lymph node stage may have clinical importance among NSCLC patients with M1a disease

Study shows lymph node stage may have clinical importance among NSCLC patients with M1a disease

Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis. [More]
Researchers identify tantalizing target in fight against aggressive form of lung cancer

Researchers identify tantalizing target in fight against aggressive form of lung cancer

Researchers at the University of Virginia School of Medicine have discovered a flaw in the armor of the most aggressive form of lung cancer, a weakness that doctors may be able to exploit to slow or even stop the disease. [More]
Added benefit of lung cancer drug not proven, says IQWiG

Added benefit of lung cancer drug not proven, says IQWiG

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. [More]
Study shows leptomeningeal metastases more prevalent in NSCLC patients with EGFR mutations

Study shows leptomeningeal metastases more prevalent in NSCLC patients with EGFR mutations

Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. [More]
Wistar scientists discover marker for PMN-MDSCs in the blood of cancer patients

Wistar scientists discover marker for PMN-MDSCs in the blood of cancer patients

Myeloid-derived suppressor cells (MDSCs) are a population of immune cells that have been implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy. [More]
Scientists identify new way to impair tumour growth in lung cancer

Scientists identify new way to impair tumour growth in lung cancer

Researchers from the Cancer Science Institute of Singapore at the National University of Singapore, in collaboration with Harvard Stem Cell Institute, have discovered a new way in which the development of lung cancer can be stopped. [More]
Research could help develop better therapies for new subtype of adenocarcinoma  patients

Research could help develop better therapies for new subtype of adenocarcinoma patients

Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. [More]
Cell-free DNA test could help identify liver transplant patients with acute rejection

Cell-free DNA test could help identify liver transplant patients with acute rejection

Today, researchers presented findings at the 68th AACC Annual Scientific Meeting that DNA found circulating in the bloodstream—known as cell-free DNA—can be used to identify liver transplant patients with acute rejection with greater accuracy than conventional liver function tests. [More]
Liquid biopsies hold potential for detecting NSCLC EGFR mutations, predicting cancer recurrence

Liquid biopsies hold potential for detecting NSCLC EGFR mutations, predicting cancer recurrence

Three manuscripts published in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer, explored the versatility of liquid biopsies by identifying EGFR mutations using circulating tumor DNA (ctDNA) in urine and plasma and examining circulating tumor cells (CTCs) in plasma to predict the risk of lung cancer recurrence after surgical resection. [More]
UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers have developed a new breakthrough combination treatment that utilizes a vaccine to activate an immune response against advanced brain tumors. [More]
Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition. [More]
Advertisement